Key result
Myocardial matrix metalloproteinase expression, including an over four-fold increase in MMP-3, contributes to left ventricular remodeling in dilated cardiomyopathy and represents a therapeutic target.
Why the study?
Does broad-spectrum pharmacological MMP inhibition attenuate left ventricular dilation and improve pump function in the setting of developing heart failure?
Population
Experimental and clinical forms of dilated cardiomyopathy, including ischemic and non-ischemic human DCM…
Design
Review
Authors
Loading...
MMP overexpression may promote remodeling in dilated cardiomyopathy; leaves open whether inhibition improves outcomes.
Does broad-spectrum pharmacological MMP inhibition attenuate left ventricular dilation and improve pump function in the setting of developing heart failure?
Increased myocardial matrix metalloproteinase expression and activity contribute to left ventricular remodeling in cardiomyopathy, highlighting MMP inhibition as a potential therapeutic target for heart failure.
Francis G. Spinale (2000) conducted a review in Dilated cardiomyopathy and heart failure. Pharmacological MMP inhibitor was evaluated. Myocardial matrix metalloproteinase expression, including an over four-fold increase in MMP-3, contributes to left ventricular remodeling in dilated cardiomyopathy and represents a therapeutic target.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: